



Bio-T has developed a cloud software that enables medical device manufacturers to seamlessly convert their medical devices to IoT creating a data collection system that manages their device and provides remote care.

Website: biot-med.com

COMPANY OVERVIEW

Model: **B2B, SaaS**

Founded: **2017**

Location: **Israel**

Industries Verticals: **Medical device and pharma companies/IoT**

Potential Market Size: **Multi billion-dollar market**

Funds raised: **2M USD**

Company stage: **Initial revenue**

PROPOSITION

bio-T™ is helping medical device companies build remote care solutions much quicker by bridging two critical gaps shared by many of them. The gaps are complying with patient data regulations and delivering effective remote care workflows that patients and caregivers adhere to.

Guided by the former CEO of Rambam medical center and the former CTO of 8200's cyber division, bio-T is providing a cloud software enabling to upgrade any standalone device to a remote care solution in a snap!

The patent-pending bio-T Engine™ is a one stop shop for vendors, securely supporting all the dataway from device connectivity to patient interaction and behavior analysis.

The values to vendors are short time to market, assurance of cyber & regulation risks, and more patient outcome features than what they would have done in-house.

bio-T is leading the market and is already used today for powering class III and other FDA & CE-cleared connected medical device solutions across the US, EU and globally.

HIGHLIGHTS

Completed MVP and launched with initial clients, including \$BN mkt cap companies.

Used by thousands of patients in the US market

Closely partnered with Amazon AWS

Growing pipeline with multiple Top 10 lifescience companies

TEAM



Guy Vinograd CEO

IoMT key opinion leader with 8 years of experience building and managing multiple tech ventures



Boaz Vaizler COO

15+ years R&D veteran and entrepreneur with startup exit experience



Daniel Adler CBO

15+ years B2B2B sales expert with proven success launching Valens and Nice to new markets